A carregar...
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
Background: In 2014, six of the top ten blockbuster medicines were monoclonal antibodies. This multibillion-dollar market with expiring patents is the main driver for the development of biosimilar mAbs. With the ever-increasing cost of healthcare and the economic pressure to reduce or sustain health...
Na minha lista:
| Publicado no: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4925708/ https://ncbi.nlm.nih.gov/pubmed/27445826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00193 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|